These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12555156)

  • 1. From mouse to man: understanding heart failure through genetically altered mouse models.
    Chu G; Haghighi K; Kranias EG
    J Card Fail; 2002 Dec; 8(6 Suppl):S432-49. PubMed ID: 12555156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac sarcomeric function, small G-protein signaling, and heart failure.
    Vahebi S; Solaro RJ
    Panminerva Med; 2005 Sep; 47(3):133-42. PubMed ID: 16462722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
    Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
    Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy.
    Wilkins BJ; Molkentin JD
    Biochem Biophys Res Commun; 2004 Oct; 322(4):1178-91. PubMed ID: 15336966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure.
    Wang J; Xu N; Feng X; Hou N; Zhang J; Cheng X; Chen Y; Zhang Y; Yang X
    Circ Res; 2005 Oct; 97(8):821-8. PubMed ID: 16151019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure.
    van Oort RJ; van Rooij E; Bourajjaj M; Schimmel J; Jansen MA; van der Nagel R; Doevendans PA; Schneider MD; van Echteld CJ; De Windt LJ
    Circulation; 2006 Jul; 114(4):298-308. PubMed ID: 16847152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fiber orientation on propagation: electrical mapping of genetically altered mouse hearts.
    Punske BB; Taccardi B; Steadman B; Ershler PR; England A; Valencik ML; McDonald JA; Litwin SE
    J Electrocardiol; 2005 Oct; 38(4 Suppl):40-4. PubMed ID: 16226072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model.
    Janczewski AM; Zahid M; Lemster BH; Frye CS; Gibson G; Higuchi Y; Kranias EG; Feldman AM; McTiernan CF
    Cardiovasc Res; 2004 Jun; 62(3):468-80. PubMed ID: 15158139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of calcium cycling defects in advanced heart failure toward molecular therapy.
    Hoshijima M; Knöll R; Pashmforoush M; Chien KR
    J Am Coll Cardiol; 2006 Nov; 48(9 Suppl 1):A15-23. PubMed ID: 17084280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac hypertrophy: a risk factor for QT-prolongation and cardiac sudden death.
    Kang YJ
    Toxicol Pathol; 2006; 34(1):58-66. PubMed ID: 16507545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospholipase C epsilon modulates beta-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy.
    Wang H; Oestreich EA; Maekawa N; Bullard TA; Vikstrom KL; Dirksen RT; Kelley GG; Blaxall BC; Smrcka AV
    Circ Res; 2005 Dec; 97(12):1305-13. PubMed ID: 16293787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GATA transcription factors in the developing and adult heart.
    Pikkarainen S; Tokola H; Kerkelä R; Ruskoaho H
    Cardiovasc Res; 2004 Aug; 63(2):196-207. PubMed ID: 15249177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The pathophysiological mechanism of cardiac development and hypertrophy, and heart failure].
    Hasegawa H; Komuro I
    Nihon Rinsho; 2003 May; 61(5):704-7. PubMed ID: 12754991
    [No Abstract]   [Full Text] [Related]  

  • 15. Manipulating the contractile apparatus: genetically defined animal models of cardiovascular disease.
    Dalloz F; Osinska H; Robbins J
    J Mol Cell Cardiol; 2001 Jan; 33(1):9-25. PubMed ID: 11133219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
    Oudit GY; Crackower MA; Eriksson U; Sarao R; Kozieradzki I; Sasaki T; Irie-Sasaki J; Gidrewicz D; Rybin VO; Wada T; Steinberg SF; Backx PH; Penninger JM
    Circulation; 2003 Oct; 108(17):2147-52. PubMed ID: 12963636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
    Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Kitamura S; Tomoike H; Hori M; Kitakaze M
    Circulation; 2004 Aug; 110(6):692-9. PubMed ID: 15262839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and function of the human mineralocorticoid receptor: lessons from transgenic mouse models.
    Le Menuet D; Viengchareun S; Muffat-Joly M; Zennaro MC; Lombès M
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):127-36. PubMed ID: 15134811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation.
    Engelhardt S; Hein L; Dyachenkow V; Kranias EG; Isenberg G; Lohse MJ
    Circulation; 2004 Mar; 109(9):1154-60. PubMed ID: 14967726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animal models for heart failure.
    Gupta S; Sen S
    Methods Mol Med; 2006; 129():97-114. PubMed ID: 17085807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.